TACTILE SYSTEMS TECHNOLOGY INC (TCMD)
Health Care · Medical Devices & Equipment (Home Health) · NASDAQ
A medical technology company providing clinically proven, at-home therapy solutions for lymphedema, chronic venous insufficiency, and respiratory conditions.
What TACTILE SYSTEMS TECHNOLOGY INC does
Tactile Medical is a medical technology company focused on providing home-based therapy for underserved chronic conditions. The company specializes in vascular disease, specifically lymphedema and chronic venous insufficiency, as well as airway clearance therapy for patients with chronic respiratory conditions. It utilizes a direct-to-patient model for its lymphedema portfolio and a durable medical equipment (DME) distribution model for its respiratory devices.
Recent developments
In Q2 2026, the company launched its next-generation AffloVest airway clearance system and entered into an exclusive distribution agreement with ElastiMed for the MyoSleeve compression device for Veterans and service members. The company also reported progress in integrating LymphaTech to expand its lymphedema care continuum.
From TACTILE SYSTEMS TECHNOLOGY INC's filing of 2026-08-10.
Themes: at-home healthcare, vascular disease management, lymphedema therapy, respiratory care, oncology patient support, medical devices
Fundamentals
- Price$22.12 as of 2026-10-08 close
- Market cap$501M as of 2026-08-06 (share count; price 2026-10-08)
- 1-year return+48.5% 2025-10-08 close $14.90 → 2026-10-08 close $22.12
- P/E25.08 as of 2026-10-08
- Net margin+5.8% FY2025, SEC XBRL
- Gross margin+75.9% FY2025, SEC XBRL
- ROE+8.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+17.2% as of 2026-09-02
- Revenue CAGR (3y)+10.1% SEC XBRL
- Beta0.72 as of 2026-09-02
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How TCMD compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How TACTILE SYSTEMS TECHNOLOGY INC looks technically
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) is trading 16.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 23 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 41.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 16.5% below its 200-day average, the long-term trend line — a long-term downtrend | -16.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.84 | $23.84 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.49 | $26.49 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 23.3. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 23 trading days ago — a "death cross", a bearish long-term signal | 23 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.61 to $23.30) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 30.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $37.77 | $37.77 |
|---|---|---|
| From the 52-week high | it is 41.4% below its 52-week high (its highest price of the past year) | -41.4% |
| Above the 52-week low | it is 64.1% above its 52-week low (its lowest price of the past year) | +64.1% |
| Below the 52-week high | it is 41.4% below its highest point of the past year | 41.4% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $76.63 (set on 2019-02-20) | $76.63 |
| Given back of the 52-week move | over the past year its closes ranged ($13.83 to $33.05), and it has given back around half of its rise from last year’s low — 57% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.56 to $21.17. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 56.9% |
| From the all-time high | it is 71.1% below its all-time high | -71.1% |
| Nearest price level | it is trading 1.9% below a resistance level at $22.54 — a price it turned at twice since 2025-11-18, most recently on 2026-05-15. Since 2024-10-08 it has 8 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.9% |
| All-time low | its lowest closing price on record is $6.29 (set on 2022-06-13) | $6.29 |
| Above the all-time low | it is 251.7% above its all-time low | +251.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7172 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7172 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $21.81 and $23.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $21.81 – $22.41 – $23.02 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 6.1 daily ranges below its 200-day average price (16.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.36× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 19.9% below the previous close 41 sessions ago and has not traded back through the level it left behind at 29.14 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -19.9% |
| Gap filled | a 2.5% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.8 percentage points (the stock gained 1.8% while the market gained 1.0%) | +0.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 30.0 percentage points (the stock lost 26.2% while the market gained 3.8%) | -30.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 27.4 percentage points (the stock lost 10.0% while the market gained 17.5%) | -27.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 33.5 percentage points (the stock gained 48.5% while the market gained 15.0%) | +33.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -10.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $26.43 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -16.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $23.29 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -5.0% |
Price levels it has turned at before
TCMD last closed at $22.12 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $22.54 | Resistance | 1.9% above the last close | turned there twice · 2025-11-18 to 2026-05-15 |
| $21.19 | Support | 4.2% below the last close | turned there twice · 2024-11-26 to 2026-09-08 |
| $23.19 | Resistance | 4.8% above the last close | turned there three times · 2026-04-13 to 2026-09-28 |
| $25.41 | Resistance | 14.9% above the last close | turned there three times · 2025-11-11 to 2026-06-24 |
| $18.07 | Support | 18.3% below the last close | turned there three times · 2024-12-27 to 2025-02-18 |
| $14.73 | Support | 33.4% below the last close | turned there three times · 2024-10-18 to 2025-10-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $23.30.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.27 and $19.85 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$39.00 range $38.00 – $40.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TCMD
- Consensus EPS estimate$0.335 next reporting period, as of 2026-10-06
- Estimate change, 30 days+$0.165 (+97.1%) from $0.17, on 2026-09-01, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Changes to Medicare coverage or reimbursement criteria for existing or new products could significantly reduce revenue.","Reliance on third-party payers and complex reimbursement processes for insurance claims.","Intense competition in the medical device market which could impact pricing and market share."]
What changed in the latest 10-Q
AI-assisted comparison of TCMD's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-04) adds statement: 'Nimbl has replaced most orders for our Entre system and we expect will continue to do so.'
- Newer filing (2026-05-04) adds specific employee count comparison: '172 account managers and 163 specialists for lymphedema as of March 31, 2026' vs. '161 account managers and 103 specialists as of March 31, 2025'
- Newer filing (2026-05-04) adds financial results for Q1 2026: 'revenue of $75.3 million and net loss of $1.8 million' compared to Q1 2025 'revenue of $61.3 million and net loss of $3.0 million'
- Removed:
- Older filing (2025-11-03) provided revenue and income metrics for nine-month periods ended September 30, 2025 and 2024 (three different time period comparisons). Newer filing removes all nine-month and year-over-year comparisons.
- Older filing (2025-11-03) stated lymphedema products represented '84% and 88% of revenue' for nine months ended September 30, 2025 and 2024. Newer filing removes historical percentages.
- Older filing (2025-11-03) stated AffloVest represented '16% and 12% of revenue' for nine months ended September 30, 2025 and 2024. Newer filing removes the historical 2024 percentage.
- Older filing (2025-11-03) included employee comparisons as of September 30, 2025 and 2024. Newer filing replaces these with March 31, 2026 and 2025 data.
- Older filing (2025-11-03) included section titled 'Results of Operations' with detailed comparison table. Newer filing's excerpt ends before this section begins.
- Reworded:
- Mission statement changed from 'reveal and treat people with underserved chronic conditions' (older) to 'help people suffering from chronic diseases live better and care for themselves at home' (newer)
- Overview focus changed from emphasizing specific clinician channels (oncology-related, vascular disease, wound/vein/lymphatic clinics) in older filing to emphasizing therapeutic focus areas (vascular disease, oncology, respiratory) in newer filing
- Older filing stated 'Across our two product lines, our home-based solutions deliver cost-effective, clinically proven and long-term treatment for indicated patients.' Newer filing changes to similar statement but with different emphasis structure regarding scalable platform and home care delivery model recognition.
- Revenue percentages changed from '84% and 88% of revenue' (older, nine-month data) to '83% of our revenue in each of the three months' (newer, three-month data, single period reported)
- AffloVest revenue percentage changed from '16% and 12%' (older, nine-month comparison) to '17%' (newer, single three-month period)
- Notes:
- The two filings cover different reporting periods (Q1 ended March 31, 2026 vs. Q3 ended September 30, 2025), which explains some metric differences
- The newer filing excerpt appears incomplete—it ends mid-section before 'Results of Operations' section begins, while the older filing includes that section header
- Employee count changes reflect different reference dates (March 31 vs. September 30) rather than necessarily reflecting growth/decline direction
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($323243) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 2 sells ($436647) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TCMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TCMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,288,807
- Reported value $97,940,665
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TCMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TCMD had 2,815,055 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
TCMD had 12.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.42 days to cover at the same settlement.
- Reported short interest (shares) 2,815,055
- Short interest (% of shares outstanding) 12.4%
- Prior settlement (shares) 2,610,235
- Reported change 7.85%
- Days to cover (reported) 10.42
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- BioCompression Systems
- Lympha Press
- Hill-Rom (Baxter International, BAX)
- ResMed (RMD)
- Philips (PHG)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TCMD vs…
TACTILE SYSTEMS TECHNOLOGY INC is found in…
Frequently asked questions
What does TACTILE SYSTEMS TECHNOLOGY INC (TCMD) do?
Tactile Medical is a medical technology company focused on providing home-based therapy for underserved chronic conditions. The company specializes in vascular disease, specifically lymphedema and chronic venous insufficiency, as well as airway clearance therapy for patients with chronic respiratory conditions. It utilizes a direct-to-patient model for its lymphedema portfolio and a durable medical equipment (DME) distribution model for its respiratory devices.
What sector is TACTILE SYSTEMS TECHNOLOGY INC (TCMD) in?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) is classified in the Health Care sector. Its industry is Medical Devices & Equipment (Home Health). It trades on NASDAQ.
Who are TACTILE SYSTEMS TECHNOLOGY INC's (TCMD) competitors?
Notable peers of TACTILE SYSTEMS TECHNOLOGY INC (TCMD) include BioCompression Systems, Lympha Press, Hill-Rom (Baxter International, BAX), ResMed and Philips. This peer set is informational only — not financial advice.
Is TACTILE SYSTEMS TECHNOLOGY INC (TCMD) overbought or oversold right now?
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TCMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.